Last reviewed · How we verify
Tenofovir/Emtricitabine and efavirenz
Tenofovir/Emtricitabine and efavirenz is a Antiretroviral combination therapy (NRTI + NNRTI) Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients.
This combination inhibits HIV reverse transcriptase and integrase to block viral replication and reduce viral load in HIV-infected patients.
This combination inhibits HIV reverse transcriptase and integrase to block viral replication and reduce viral load in HIV-infected patients. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Tenofovir/Emtricitabine and efavirenz |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) that compete with natural substrates to terminate viral DNA chain elongation. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds and inhibits the reverse transcriptase enzyme. Together, these three agents suppress HIV replication through complementary mechanisms targeting the same enzyme.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Dizziness
- Nausea
- Headache
- Rash
- Neuropsychiatric effects (dizziness, impaired concentration, abnormal dreams)
- Hepatotoxicity
- Lactic acidosis
- Lipodystrophy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (PHASE1)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir/Emtricitabine and efavirenz CI brief — competitive landscape report
- Tenofovir/Emtricitabine and efavirenz updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Tenofovir/Emtricitabine and efavirenz
What is Tenofovir/Emtricitabine and efavirenz?
How does Tenofovir/Emtricitabine and efavirenz work?
What is Tenofovir/Emtricitabine and efavirenz used for?
Who makes Tenofovir/Emtricitabine and efavirenz?
What drug class is Tenofovir/Emtricitabine and efavirenz in?
What development phase is Tenofovir/Emtricitabine and efavirenz in?
What are the side effects of Tenofovir/Emtricitabine and efavirenz?
What does Tenofovir/Emtricitabine and efavirenz target?
Related
- Drug class: All Antiretroviral combination therapy (NRTI + NNRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Compare: Tenofovir/Emtricitabine and efavirenz vs similar drugs
- Pricing: Tenofovir/Emtricitabine and efavirenz cost, discount & access